Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label trial of sublingual oxytocin for prevention of postpartum hemorrhage after vaginal delivery
PACTR202505778331886Phase 2Recruiting
- Sponsor
- Chemo
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Chemo. Primary endpoint: Primary efficacy endpoint. Started Oct 2025; status: recruiting.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202505778331886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505778331886.